Expertise in
3
conditions

Zan J. Shen

No. 600, Yishan Road, 
Shanghai, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
3
conditions
No. 600, Yishan Road, 
Shanghai, CN 

Overview

Zan Shen practices practicing medicine in Shanghai, China.

Shen is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Osteosarcoma, Adult Soft Tissue Sarcoma, Bone Tumor, Lung Metastases, and Vertebroplasty.

They are actively involved in clinical research, co-authoring 138 peer reviewed articles and participating in 2 clinical trials.

Locations

No. 600, Yishan Road, Shanghai, 200233, China
Other Locations
600 Yishan Rd, Shanghai, 200233, China
No. 600, Yishan Road, Xuhui, 200233, China
Shanghai Jiao Tong University Affiliated Sixth People's Hospital 600 Yishan Rd, Shanghai, 200233, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Recruiting
Publish Date: February 25, 2026
Intervention Type: Drug
Study Drugs: Anlotinib, Decarbazine
Study Phase: Phase 3

138 Total Publications

Drug-eluting bead transarterial chemoembolization combined with immune checkpoint inhibitors is associated with improved progression-free survival in locally advanced or metastatic sarcoma: a retrospective propensity score-matched analysis.
Drug-eluting bead transarterial chemoembolization combined with immune checkpoint inhibitors is associated with improved progression-free survival in locally advanced or metastatic sarcoma: a retrospective propensity score-matched analysis.
Journal: Therapeutic advances in medical oncology
Published: February 15, 2026

Frequently Asked Questions about Zan J. Shen

Is Zan J. Shen a top-rated expert for Osteosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Zan J. Shen is classified as an Distinguished expert for Osteosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Zan J. Shen participate in research or clinical trials?

Yes. Zan J. Shen has published 138 articles and abstracts on conditions like Osteosarcoma. You can view a list of Zan J. Shen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Shen's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile